Allergy Therapeutics plc (LON:AGY – Get Free Report) shares reached a new 52-week high during trading on Tuesday . The stock traded as high as GBX 11.50 and last traded at GBX 11.29, with a volume of 192463 shares trading hands. The stock had previously closed at GBX 10.90.
Allergy Therapeutics Stock Performance
The company has a market cap of £700.12 million, a price-to-earnings ratio of -15.83, a P/E/G ratio of -30.70 and a beta of 1.40. The company has a current ratio of 1.63, a quick ratio of 1.48 and a debt-to-equity ratio of 835.48. The stock’s 50 day moving average price is GBX 8.97 and its 200 day moving average price is GBX 8.32.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Featured Stories
- Five stocks we like better than Allergy Therapeutics
- How to Use the MarketBeat Excel Dividend Calculator
- Pfizer Adds to Its Big Bet on Weight Loss Drugs
- How to Effectively Use the MarketBeat Ratings Screener
- ServiceNow’s $7 Billion Gamble: Panic or Opportunity?
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Dell and HP Are Raising Prices—And Investors Should Take Note
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
